Viroblock SA, a Swiss manufacturer of medical facemask and personal
protective equipment is proud to introduce a revolutionary new anti-‐viral mask. Viroblock uses cholesterol depletion technology that traps and kills on pass through air 99.9995% of H1N1, 99.999% of H5N1 and 99.997% of Coronavirus. Thanks to its special filtration design and patented technology Viroblock mask combines anti-‐viral properties with superb wearing comfort and excellent breathability.
Viroblock masks are fast acting against a broad spectrum of viruses. The mask is CE certified and is compliant with both European Medical Device Directive (EN14683) and European Personal Protective Equipment Directive (EN149). Aerobiology testing shows that Viroblock mask are 100 times better than ordinary respirator mask and 10,000 times better that regular surgical mask.
Viroblock’s target is to introduce its unique anti-‐viral mask to EU, Taiwan and Asia supplying leading hospitals, healthcare clinics and dental practices. Governments and Health Authorities worldwide see Viroblock masks as ideal option for the stockpiling of medical supplies in anticipation of potential viral outbreaks.
For more information, visit www.viroblock.com and Viroblock booth No A1012 at Medicare Taiwan 2013 slated for June 20-‐23 at the Exhibition Hall 1, Taipei World Trade Center.
